Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Leslie Popplewell**, MD, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, MDBS, Tanya Siddiqi, MD, Nicole Tsai, Fay Zuo, Rosie Abary, Ji-lian Cai, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD, Leona Holmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4515.

https://doi.org/10.1182/blood.V130.Suppl_1.4515.4515

Published: 2017

Journal Articles

Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL

Blood (2017) 130 (Supplement 1): 1442.

https://doi.org/10.1182/blood.V130.Suppl_1.1442.1442

Published: 2017

Journal Articles

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Amrita Y. Krishnan, MD, Joycelynne Palmer, PhD, Auayporn P. Nademanee, MD, Robert Chen, Leslie L. Popplewell, MD, Nicole Tsai, MS, James F. Sanchez, PhD, Jennifer Simpson, Ricardo Spielberger, MD, Dave Yamauchi, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 3179.

https://doi.org/10.1182/blood.V126.23.3179.3179

Published: 2015

Journal Articles

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Robert W Chen, MD, Joycelynne Palmer, PhD, Peter Martin, MD, Nicole Tsai, Young Kim, MD, Michelle Mott, RN, Firoozeh Sahebi, Tanya Siddiqi, MD, Leslie L. Popplewell, MD, John P. Leonard, MD, Tsiporah B. Shore, Stephen J. Forman

Blood (2014) 124 (21): 501.

https://doi.org/10.1182/blood.V124.21.501.501

Published: 2014

Journal Articles

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

Amrita Krishnan, M.D., Joycelynne Palmer, PhD, Auayporn Nademanee, M.D., Andrew Raubitschek, MD, Dave Yamauchi, Neil Martin Kogut, MD, Laura Federico, Nicole Tsai, Stephen Forman, M.D.

Blood (2010) 116 (21): 32.

https://doi.org/10.1182/blood.V116.21.32.32

Published: 2010

Journal Articles

HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL).

Amrita Krishnan, MD, FACP, John Zaia, MD, Joseph Alvarnas, MD, Neil Kogut, MD, Ricardo Spielberger, MD, Michelle Wardlow, RN, Nicole Tsai, MS, Tanya Paris, BS, Stephen J Forman, MD

Blood (2008) 112 (11): 2181.

https://doi.org/10.1182/blood.V112.11.2181.2181

Published: 2008

Journal Articles

Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).

Margaret R. O’Donnell, MD, Anthony S. Stein, MD, Ryotaro Nakamura, MD, Marilyn L. Slovak, PhD, Nicole Tsai, PhD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Ricardo Spielberger, MD, Eileen P. Smith, MD, David S. Snyder, MD, Pablo M. Parker, MD, Leslie Popplewell, MD, Vinod Pullarkat, MD, Chatchada Karanes, MD, Neil Kogut, MD, George Somlo, MD, Stephen J. Forman, MD

Blood (2007) 110 (11): 1089.

https://doi.org/10.1182/blood.V110.11.1089.1089

Published: 2007

Journal Articles

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

Amrita Y. Krishnan, MD, Joycelynne M. Palmer, PhD, Smita C. Bhatia, MD, MPH, Auayporn Nademanee, MD, Stephen J. Forman, MD, Andrew Raubitschek, MD, Arturo M. Molina, MD, Henry Fung, MD, Peter Falk, MD, Marilyn J. Slovak, MD, Nicole Tsai, MS, Jennifer Simpson, BA, Ravi Bhatia, MD

Blood (2007) 110 (11): 1082.

https://doi.org/10.1182/blood.V110.11.1082.1082

Published: 2007

Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

Auayporn P. Nademanee, MD, Amrita Krishnan, M.D, Nicole Tsai, MS, MPH, Joycelynne Palmer, Ph.D., Arturo Molina, M.D., Henry C. Fung, M.D., David Yamauchi, M.D, Neil Martin Kogut, M.D., Stephen J. Forman, M.D., Andrew Raubitschek, M.D.

Blood (2006) 108 (11): 327.

https://doi.org/10.1182/blood.V108.11.327.327

Published: 2006

Journal Articles

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Auayporn P. Nademanee, MD, Jasmine M. Zain, M.D., Joycelynne Palmer, Ph.D., Nicole Tsai, M.S., M.P.H., Neil Martin Kogut, M.D., Amrita Krishnan, M.D., Leslie Popplewell, M.D., Roberto Rodriguez, M.D., Eileen Patricia Smith, M.D., Stephen J. Forman, M.D.

Blood (2006) 108 (11): 3060.

https://doi.org/10.1182/blood.V108.11.3060.3060

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells.

Amrita Y. Krishnan, MD, John A. Zaia, MD, John J. Rossi, PhD, Arturo Molina, MD, Mingjie Li, PhD, Wendy Lee, Ramesh Akkina, DVM, Nicole Tsai, MS, Shirley Li, MD, Priscilla Yam, FIBMS, Haitang Li, Jiing-Kuan Yee, PhD, David Hsu, PhD, Larry Couture, PhD, David DiGiusto, PhD, Stephen J. Forman, MD

Blood (2006) 108 (11): 491.

https://doi.org/10.1182/blood.V108.11.491.491

Published: 2006

NARROW

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Therapy-Related ALL Has Distinct Clinical and Pathologic Features Compared to De Novo ALL

Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?

Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT

Comparative Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy (RIT) Based Conditioning Versus Total Body Irradiation (TBI) for High-Risk Diffuse Large Cell Lymphoma (DLCL): Toxicity and Efficacy

HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL).

Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

90 Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose Therapy (HDT) Followed by Autologous Stem Cell Transplant (ASCT) May Improve Survival in Patients with Poor-Risk Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Results of a Retrospective Comparative Analysis.

The Impact of Disease Status on the Outcome of High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) for Peripheral T-Cell Lymphoma (PTCL).

Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only